KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Pacific Biosciences Of California (PACB) over the last 16 years, with Q3 2025 value amounting to 101.13%.

  • Pacific Biosciences Of California's EBIT Margin rose 591900.0% to 101.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 430.63%, marking a year-over-year decrease of 1945200.0%. This contributed to the annual value of 307.97% for FY2024, which is 1411700.0% down from last year.
  • As of Q3 2025, Pacific Biosciences Of California's EBIT Margin stood at 101.13%, which was up 591900.0% from 112.79% recorded in Q2 2025.
  • In the past 5 years, Pacific Biosciences Of California's EBIT Margin registered a high of 101.13% during Q3 2025, and its lowest value of 1154.51% during Q1 2025.
  • For the 5-year period, Pacific Biosciences Of California's EBIT Margin averaged around 258.42%, with its median value being 191.64% (2022).
  • The largest annual percentage gain for Pacific Biosciences Of California's EBIT Margin in the last 5 years was 3754900bps (2025), contrasted with its biggest fall of -9448700bps (2025).
  • Quarter analysis of 5 years shows Pacific Biosciences Of California's EBIT Margin stood at 179.56% in 2021, then plummeted by -77bps to 318.37% in 2022, then skyrocketed by 53bps to 150.02% in 2023, then tumbled by -160bps to 390.14% in 2024, then skyrocketed by 74bps to 101.13% in 2025.
  • Its EBIT Margin was 101.13% in Q3 2025, compared to 112.79% in Q2 2025 and 1154.51% in Q1 2025.